D.E. Shaw & Co
KNTE

D.E. Shaw & Co’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

D.E. Shaw & Co’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-150,695
Closed -$357K – 4853
2023
Q4 		$357K Buy
150,695
+94,885
+170% +$168K ﹤0.01% 3676
2023
Q3 		$78.1K Sell
55,810
-4,299
-7% -$10.3K ﹤0.01% 3878
2023
Q2 		$182K Buy
+60,109
New +$232K ﹤0.01% 3758
2022
Q1 		– Sell
-13,989
Closed -$248K – 6071
2021
Q4 		$248K Sell
13,989
-14,479
-51% -$305K ﹤0.01% 4776
2021
Q3 		$655K Buy
28,468
+7,711
+37% +$168K ﹤0.01% 3907
2021
Q2 		$483K Sell
20,757
-2,088
-9% -$53.1K ﹤0.01% 4054
2021
Q1 		$712K Buy
+22,845
New +$796K ﹤0.01% 3326

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co's KNTE Position: Q1 2024 in Review

D.E. Shaw & Co sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q1 2024, closing a stake of 150,695 shares — an estimated $357K sold.

D.E. Shaw & Co first reported a position in KNTE in Q1 2021 and held it in 7 quarters. The position peaked at $712K in Q1 2021. 56 funds tracked by Wall St. Rank hold KNTE as of Q1 2024.

  • D.E. Shaw & Co reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • D.E. Shaw & Co sold 150,695 Kinnate Biopharma Inc. Common Stock shares in Q1 2024, an estimated $357K.
  • D.E. Shaw & Co first reported a position in Kinnate Biopharma Inc. Common Stock in Q1 2021 and held it in 7 quarters.
  • D.E. Shaw & Co's Kinnate Biopharma Inc. Common Stock position peaked at $712K in Q1 2021.
  • 56 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q1 2024.

Based on D.E. Shaw & Co's 13F filing for Q1 2024, filed 15 May 2024.